Login
$ARVN
$6.77 -$0.05 (0.73%) Live

$ARVN 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –

04 Aug 2026 8-K: Results of Operations and Financial Condition

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 24, 2026, Arvinas, Inc. (the "Company") held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote upon the three proposals set forth below, each of which is described in greater detail in the Company's P...

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3,...

16 Jun 2026 8-K: Other Events

As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvin...

02 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Representatives of Arvinas, Inc. (the "Company") intend to use a presentation (the "Investor Presentation") at various meetings with investors, analysts or others from time to time, including in a fireside chat at the Jefferies Global He...

12 May 2026 8-K: Results of Operations and Financial Condition

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline -

12 May 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Exhibit 99.1 Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) – Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential ...

01 May 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 VEPPANU is a trademark of Arvinas Operations, Inc. Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – VEPPANU™ is the first-and-only FDA-approved PROTAC, ...

18 Mar 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days – ARV-102 reduced endolysosomal and neuroinflammatory biomark...

24 Feb 2026 8-K: Results of Operations and Financial Condition

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 –

12 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Change in President, Chief Executive Officer and Chair of the Board of Directors

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition – Dat...

05 Nov 2025 8-K: Results of Operations and Financial Condition

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease –

24 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therap...

20 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy ...

06 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders® – ARV-102 was well tolerated in clinical ...

17 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure +1 more

Exhibit 99.1 Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant ...

08 Aug 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistical...

06 Aug 2025 8-K: Results of Operations and Financial Condition

– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer –

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support